Wright Peter F, Karron Ruth A, Belshe Robert B, Shi Jian R, Randolph Valerie B, Collins Peter L, O'Shea Alice F, Gruber William C, Murphy Brian R
Vanderbilt University, Nashville, TN, USA.
Vaccine. 2007 Oct 16;25(42):7372-8. doi: 10.1016/j.vaccine.2007.08.014. Epub 2007 Aug 28.
Early in the development of respiratory syncytial virus (RSV) vaccines severe disease occurred in children after receipt of formalin-inactivated RSV vaccine. Continuing efforts to develop an appropriately attenuated and immunogenic live RSV vaccine have given opportunities to assure that live vaccines are safe through surveillance of children after vaccination. In the present study, the rate of RSV-associated upper respiratory tract illness in 388 children was lower in RSV vaccinated children than in controls (14% versus 20% in a 6-24 month old group and 16% versus 25% in infants). Additionally, there was no evidence that vaccination predisposed to more severe lower respiratory tract illness. Thus infection with a series of live attenuated RSV vaccines did not result in enhanced disease upon infection with wild type RSV. The impact of RSV during this surveillance will inform the design of future efficacy studies with RSV vaccines.
在呼吸道合胞病毒（RSV）疫苗研发早期，儿童接种福尔马林灭活RSV疫苗后出现了严重疾病。持续努力研发适当减毒且具有免疫原性的活RSV疫苗，使得通过对接种疫苗后的儿童进行监测来确保活疫苗的安全性成为可能。在本研究中，接种RSV疫苗的388名儿童中，RSV相关上呼吸道疾病的发生率低于对照组（6 - 24个月龄组中分别为14%和20%，婴儿组中分别为16%和25%）。此外，没有证据表明接种疫苗会导致更严重的下呼吸道疾病。因此，接种一系列减毒活RSV疫苗后感染野生型RSV时，不会导致疾病加重。此次监测期间RSV的影响将为未来RSV疫苗疗效研究的设计提供参考。
